1. In Vivo
  2. >>Manufacturing Focus

Lilly & Boehringer: When You Gotta Partner, You Gotta Partner

Lilly's co-promotion with Boehringer Ingelheim of duloxetine is the first time the American company has signed a major marketing deal for one of its own products. The company notes the collaboration is part of its broad commitment to partnering and that the market is intensely competitive. But the choice of duloxetine--the launch of which may be delayed indefinitely because of manufacturing problems--also represents Lilly's lowest-risk option for subsidizing the launches, and maximizing the returns from, potentially eight new products over the next few years.

Lilly has been saying for the past several years that partnerships will be crucial to its growth strategy—but in general "partnership" for Lilly has always meant in-licensing. It's off-loaded a few products (its propoxyphene (Darvon) product line, to aaiPharma Inc. 's NeoSan Pharmaceuticals Inc. unit [See Deal], and most recently, to Galen

Holdings PLC, fluoxetine hydrochloride (Serafem), its repackaging, for premenstrual dysphoric disorder, of anti-depressant fluoxetine (Prozac) [See Deal].) But Lilly...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing Focus

More from In Vivo

Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology

 
• By Sushmita Panda

Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.

Johnson & Johnson MedTech: How To Scale Digital Solutions

 
• By Natasha Barrow

J&J's EMEA head of digital solutions, Julia Fishman, talks about the hurdles in scaling digital innovation and what’s up next on J&J’s innovation road map. Robot-assisted surgery pioneer Ivo Broeders gives his perspective on the difficulties in clinical adoption.

Rising Leaders 2025: Emma Hodcroft On Taking Initiative When “Plan A” Falls Short

 
• By Anabel Costa-Ferreira

Emma Hodcroft, co-founder of Pathoplexus and a key Nextstrain contributor, stresses the importance of career flexibility for young scientists. She urges early-stage researchers to embrace curiosity, using her unconventional path as an example of how curiosity can lead to impactful success.